Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Europe is falling behind the US when it comes to approving and reimbursing new psychiatric medications, leaving patients with fewer options for conditions like schizophrenia and depression. Between 2016 and 2025, the FDA approved 38 psychiatric drugs compared to just 11 by the EMA — and only 3 of those US-approved therapies are reimbursed across five major EU markets. A new coalition, EU-MIC, is pushing to fix the regulatory and economic barriers driving this gap.
Europe is significantly trailing the US in access to innovative psychiatric medications, and experts are sounding the alarm. Between 2016 and 2025, the FDA approved 38 new drugs for mental health conditions, while the European Medicines Agency approved just 11. Even more striking: of those 38 US-approved therapies, only 3 are reimbursed across all five major EU markets — Germany, France, Italy, the Netherlands, and Spain.
The stakes are high. Mental illness costs EU member states more than €600 billion annually in healthcare spending, social benefits, and lost productivity. Conditions like schizophrenia, anxiety, and major depression often strike early in life and cause long-term disability — yet current treatments remain inadequate for many patients, with limited efficacy and burdensome side effects.
A newly formed coalition, the European Coalition for Mental Health Medicines Innovation (EU-MIC), is working to change this. Coordinated by the European College of Neuropsychopharmacology, the group is pushing for reforms to clinical trial standards, health technology assessments, and pricing structures.
Key Takeaways:
Why it matters: Patients with psychiatric disorders in Europe are losing access to potentially life-changing therapies due to structural regulatory and economic barriers — not a lack of scientific innovation. EU-MIC's push for reform could reshape how mental health drugs are developed, evaluated, and delivered across the continent.
